681464-04-0

Basic information

• Product Name: 1,4-dichloro-2,5-bis(dibromomethyl)benzene
• Synonyms: 1,4-dichloro-2,5-bis(dibromomethyl)benzene
• CAS NO: 681464-04-0
• Molecular Weight: 490.642
• Mol File: 681464-04-0.mol

Chemical Properties

• CAS DataBase Reference: 1,4-dichloro-2,5-bis(dibromomethyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-dichloro-2,5-bis(dibromomethyl)benzene(681464-04-0)
• EPA Substance Registry System: 1,4-dichloro-2,5-bis(dibromomethyl)benzene(681464-04-0)

Safety Data

• Hazardous Substances Data: 681464-04-0(Hazardous Substances Data)

Upstream product

• 1124-05-6 1,4-dichloro-2,5-dimethylbenzene 
• 7726-95-6 bromine 
• 106-42-3 para-xylene 
• 95-72-7 2-chloro-1,4-dimethyl-benzene 

Downstream Products

• 46052-84-0 2,5-dichloroterephthalic dicarboxaldehyde 
• 1445985-04-5 tert-butyl 3-(2,5-dichloro-4-formylphenyl)acrylate 
• 1445985-05-6 tert-butyl 3-[2,5-dichloro-4-(hydroxymethyl)phenyl]acrylate 
• 1445985-06-7 tert-butyl 3-[2,5-dichloro-4-(hydroxymethyl)phenyl]propanoate 
• 1445985-07-8 tert-butyl 3-[4-(bromomethyl)-2,5-dichlorophenyl]-propanoate 
• 1445985-08-9 (S)-tert-butyl 3-(2,5-dichloro-4-((2-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)pyrrolidin-1-yl)methyl)phenyl)propanoate 
• 1445985-09-0 (S)-3-(2,5-dichloro-4-((2-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)pyrrolidin-1-yl)methyl)phenyl)propanoic acid 
• 1445985-38-5 tert-butyl 3-[2,5-dichloro-4-([1-[(4-cyclopropyl-1,2,3,4-tetrahydroquinoxalin-1-yl)carbonyl]cyclopropoxy]methyl)phenyl]propatioate 
• 1445985-39-6 3-[2,5-dichloro-4-([1-[(4-cyclopropyl-1,2,3,4-tetrahydroquinoxalin-1-yl)carbonyl]cyclopropoxy]methyl)phenyl]propanoic acid 
• 1445982-24-0 3-[2,5-dichloro-4-([1-[(4-cyclopropyl-1,2,3,4-tetrahydroquinoxalin-1-yl)carbonyl]cyclopropoxy]methyl)phenyl]-N-methyl-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]propanamide trifluoroacetate 
• 1445983-24-3 (R)-(4-cyclopropyl-3,4-dihydroquinoxalin-1(2H)-yl)(3-(2,5-dichloro-4-(hydroxymethyl)benzyl)thiazolidin-4-yl)methanone 
• 1445985-54-5 (R)-methyl 2-((2,5-dichloro-4-((4-(4-cyclopropyl-1,2,3,4-tetrahydriquinoxaline-1-carbonyl)thiazolidin-3-yl)methyl)benzyl)thio)-1-methyl-1H-imidazole-5-carboxylate 
• 1445983-27-6 (R)-2-((2,5-dichloro-4-((4-(4-cyclopropyl-1,2,3,4-tetrahydriquinoxaline-1-carbonyl)thiazolidin-3-yl)methyl)benzyl)thio)-1-methyl-1H-imidazole-5-carboxylic acid 
• 1445984-68-8 5-[(2,5-dichloro-4-[[(4R)-4-[(4-cyclopropyl-1,2,3,4-tetrahydroquinoxalin-1-yl)carbonyl]-1,3-thiazolidin-3-yl]methyl]phenyl)methoxy]-N-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]pyridine-2-carboxamide 

Relevant articles and documents

Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5)

Bile acid signaling and metabolism in the gastrointestinal tract have wide-ranging influences on systemic disease. G protein-coupled bile acid receptor 1 (GPBAR1, TGR5) is one of the major effectors in bile acid sensing, with demonstrated influence on metabolic, inflammatory, and proliferative processes. The pharmacologic utility of TGR5 agonists has been limited by systemic target-related effects such as excessive gallbladder filling and blockade of gallbladder emptying. Gut-restricted TGR5 agonists, however, have the potential to avoid these side effects and consequently be developed into drugs with acceptable safety profiles. We describe the discovery and optimization of a series of gut-restricted TGR5 agonists that elicit a potent response in mice, with minimal gallbladder-related effects. The series includes 12 (TGR5 EC50: human, 143 nM; mouse, 1.2 nM), a compound with minimal systemic availability that may have therapeutic value to patients with type 2 diabetes mellitus, nonalcoholic steatohepatitis, or inflammatory bowel disease.

NON-SYSTEMIC TGR5 AGONISTS

Compounds of structure (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein R1, R2, R3, R4, R8, R9, R10, R11, R12, A1, A2, X, Y and Z are as defined herein. Uses of such compounds as TGR5 antagonists and for treatment of various indications, including Type II diabetes meletus are also provided.